RP2 and melanoma: Mechanistically, CY12-RP2 acts by suppressing PDPN-mediated activation of the Wnt/β-catenin signaling cascade, resulting in diminished PD-L1 expression in melanoma cells and subsequent activation of CD8+ T cell-mediated antitumor responses.